NIH to increase testing for COVID-19, emphasizes point of care

By staff writers

July 23, 2020 -- Researchers from the U.S. National Institutes of Health (NIH) published a framework to increase daily COVID-19 testing on July 22 in the New England Journal of Medicine.

The special report details strategies to increase the number, quality, and type of daily tests to detect SARS-CoV-2, the virus that causes COVID-19. It also addresses steps that can be taken to reduce inequalities for populations disproportionately affected by the disease.

The authors emphasized the need throughout the U.S. for low-complexity, point-of-care molecular diagnostics with rapid results. One such program to help fill this need is the NIH's Rapid Acceleration for Diagnostics (RADx) program, which was created after the $1.5 billion federal stimulus bill in April.

The RADx program includes four subprograms to help the U.S. reach a target of 6 million daily tests by December:

    1. The RADx-tech program uses a Shark Tank-like process to find diagnostic technologies with the potential to rapidly scale. It assesses applications from small and large companies using a rapid, multiple-review process. Projects deemed successful receive substantial financial assistance to move from development to commercialization.
    2. The RADx Advanced Technology program (RADx-ATP) supports companies with existing point-of-care technologies that have the ability to create immediate, substantial increases in testing capacity. It uses a rapid-response application process to identify solutions that can scale SARS-CoV-2 diagnostic production between 20,000 and 100,000 tests per day. The program also will expand "mega-labs" that increase testing capacity to 1000,000 to 250,000 tests per day.
    3. The RADx Radical (RADx-rad) program supports nontraditional testing projects that have a longer horizon, such as home-based testing. It will also support projects that use biological or physiological biomarkers to detect infection to predict disease severity.
    4. The RADx Underserved Populations (RADx-UP) program establishes community-based projects to improve access to testing in underserved and vulnerable populations. The program seeks to understand the factors that resulted in Blacks, Latinos, and American Indians/Alaska Natives having higher hospitalization and mortality rates. It also aims to build public health infrastructure that can be used for COVID-19-related public health efforts.
    Can a new national forum bust roadblocks to laboratory testing for COVID-19?
    The U.S. Department of Health and Human Services has launched the National Testing Implementation Forum as a vehicle for stakeholders to weigh in on strategies...
    3M, MIT to develop rapid COVID-19 point-of-care test
    3M and the Massachusetts Institute of Technology (MIT) are working together to develop a rapid point-of-care diagnostic for COVID-19 disease.
    Point-of-care COVID-19 antibody tests should not be used, experts advise
    Point-of-care antibody tests for COVID-19 have performance issues and should not be used beyond research purposes, according to a systematic review and...
    NIH plan targets new COVID-19 tests, point-of-care options
    The National Institutes of Health (NIH) has unveiled an initiative to speed the development and commercialization of COVID-19 testing products and technologies...
    NIH begins antibody study on undetected coronavirus cases
    The National Institutes of Health (NIH) has commenced a study to determine how many adults in the U.S. with no confirmed history of infection with SARS-CoV-2...

    Copyright © 2020

    Last Updated ls 7/23/2020 12:54:58 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.